Institut Curie

This study tests a combination of two drugs, tucatinib and trastuzumab, in people with a specific type of advanced breast cancer that has a mutation in the HER3 gene. The goal is to see if this treatment can shrink tumors or stop them from growing for at least 24 weeks. The trial…

This study tests whether a new type of PET scan (68Ga-FAPI-46) can predict if triple-negative breast cancer will completely respond to chemotherapy plus immunotherapy before surgery. About 60 women with early-stage, high-risk breast cancer will receive the scan before starting tr…

This study is for people with a type of breast cancer that has spread. It tests whether a special PET scan and blood tests can help doctors choose the best second-line treatment, either hormone therapy or chemotherapy. The goal is to see if this approach improves how long the can…

This study is testing whether regular blood tests (ctDNA monitoring) combined with a special PET scan can detect the return of triple negative breast cancer earlier than standard methods. About 450 women who have finished treatment for early-stage triple negative breast cancer wi…

This study is collecting blood samples from up to 2050 cancer patients to look for tiny pieces of tumors, called biomarkers, in the blood. The goal is to see how often these markers can be found. Participants will give blood samples over time, but their regular cancer care will n…